GlassScriptPhysician profile
Merab Joseph
NPI 1053421032
$99,478.40
in general payments reported to CMS, 2019-2025
39 companies · $12K in 2025
The $12K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24K · 2020: $17K · 2021: $8,250 · 2022: $10K · 2023: $14K · 2024: $14K · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $35K · Food and Beverage: $4,582 · Travel and Lodging: $568.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $34,987.50 |
| Food and Beverage | $4,581.52 |
| Travel and Lodging | $567.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $77,134.31 | 2019-2025 | Jardiance, Synjardy |
| Lilly USA, LLC | $16,153.61 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Medtronic Minimed, INC. | $1,524.50 | 2019 | |
| Novo Nordisk INC | $807.41 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $757.95 | 2019-2025 | Evenity, Prolia, Tepezza |
| Sanofi-Aventis U.S. LLC | $701.98 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $482.23 | 2019-2022 | |
| Abbvie INC. | $252.29 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $189.51 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $186.39 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Amneal Pharmaceuticals LLC | $120.90 | 2021-2025 | Unithroid |
| Radius Health, INC. | $99.60 | 2019-2024 | Tymlos |
| Insulet Corporation | $96.81 | 2023-2025 | Omnipod |
| Medtronic, INC. | $96.04 | 2022-2023 | Minimed 780g |
| Abbott Laboratories | $86.65 | 2019-2024 | Freestyle Libre 3 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $86.13 | 2023-2025 | |
| Pfizer INC. | $53.61 | 2019-2024 | |
| Dexcom, INC. | $50.79 | 2021-2023 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $48.37 | 2024-2025 | Korlym |
| Azurity Pharmaceuticals, INC. | $46.41 | 2023-2025 | Adthyza, Azmiro |
| Janssen Pharmaceuticals, INC | $42.19 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $37.26 | 2023-2024 | |
| Cequr Corporation | $36.79 | 2023-2025 | Cequr Simplicity |
| Recordati_rare_diseases_inc. | $33.75 | 2023-2024 | Isturisa, Signifor Lar |
| Ascendis Pharma Endocrinology INC | $32.86 | 2023-2025 | Yorvipath |
| Madrigal Pharmaceuticals | $30.99 | 2025 | Rezdiffra |
| Amryt Pharma Holdings LTD | $30.66 | 2022-2023 | Mycapssa |
| Tandem Diabetes Care, INC. | $30.48 | 2022-2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Alexion Pharmaceuticals, INC. | $29.32 | 2022-2025 | Strensiq |
| Mannkind Corporation | $28.96 | 2023-2025 | Afrezza |
| Vistapharm, INC. | $28.56 | 2021 | |
| Shire North American Group INC | $26.56 | 2019 | |
| Ibsa Pharma INC. | $25.61 | 2022 | |
| Zealand Pharma US, INC. | $16.63 | 2021 | |
| Amphastar Pharmaceuticals, INC. | $16.27 | 2024 | |
| Senseonics, Incorporated | $15.00 | 2020 | |
| Tolmar, INC. | $14.98 | 2025 | Jatenzo |
| Chiesi USA, INC. | $14.21 | 2025 | Mycapssa |
| Becton, Dickinson and Company | $11.83 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Merab Joseph listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.